12069593

Source:http://linkedlifedata.com/resource/pubmed/id/12069593

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013081, umls-concept:C0035696, umls-concept:C0035820, umls-concept:C0086418, umls-concept:C0243125, umls-concept:C0330390, umls-concept:C0439596, umls-concept:C0597357, umls-concept:C0699900
pubmed:issue	25
pubmed:dateCreated	2002-6-18
pubmed:abstractText	Prolonged agonist exposure often induces downregulation of G protein-coupled receptors (GPCRs). Although downregulation of the prototypical beta(2)-adrenergic receptor (beta(2)AR) has been extensively studied, the underlying mechanisms have yet to be resolved. As even less is known about the beta(1)-subtype, we investigated the downregulation of human beta(1)AR stably expressed in Chinese hamster fibroblasts in response to the agonist isoproterenol or the cell-permeable, chlorophenylthio-cAMP (CPT-cAMP). While either effector mediated decreases in both beta(1)AR binding activity and steady-state beta(1)AR mRNA levels, there were significant differences in their actions. Whereas agonist-mediated downregulation of beta(1)AR followed first-order kinetics, that induced by CPT-cAMP was delayed for several hours and approximately 50% of the former. Furthermore, agonist but not CPT-cAMP induced beta(1)AR internalization, and inhibiting internalization also suppressed agonist-mediated downregulation. The latter, however, was more sensitive than the former to agonist concentration (EC(50) of 0.3 vs 48 nM). Thus, at < or =1 nM agonist, downregulation occurred without internalization and with a pattern similar to that mediated by CPT-cAMP. The amounts of beta(1)AR downregulated or internalized were proportional to initial receptor levels but reached saturation at approximately 2 and 3 pmol/mg of protein, respectively. The fate of beta(1)AR protein during downregulation was determined by immunoblotting with anti-C-terminal antibodies. In agonist-treated cells, beta(1)AR protein disappeared with time and without any immunoreactive degradation products. Agonist-mediated downregulation of the human beta(1)AR appears to be a complex process that consists of both agonist- and cAMP-specific components. The former involves both receptor internalization and degradation whereas the latter involves a reduction in receptor mRNA.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0370623
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/8-((4-chlorophenyl)thio)cyclic-3',5'..., http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-1 Receptor..., http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-2 Receptor..., http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists, http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP, http://linkedlifedata.com/resource/pubmed/chemical/Isoproterenol, http://linkedlifedata.com/resource/pubmed/chemical/Leupeptins, http://linkedlifedata.com/resource/pubmed/chemical/Pepstatins, http://linkedlifedata.com/resource/pubmed/chemical/Protease Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-1, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-2, http://linkedlifedata.com/resource/pubmed/chemical/Thionucleotides, http://linkedlifedata.com/resource/pubmed/chemical/leupeptin, http://linkedlifedata.com/resource/pubmed/chemical/pepstatin
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	0006-2960
pubmed:author	pubmed-author:CurranPatricia KPK, pubmed-author:DuniganCheryl DCD, pubmed-author:FishmanPeter HPH, pubmed-author:HoangQuangQ
pubmed:issnType	Print
pubmed:day	25
pubmed:volume	41
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	8019-30
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:12069593-Adrenergic beta-1 Receptor Antagonists, pubmed-meshheading:12069593-Adrenergic beta-2 Receptor Antagonists, pubmed-meshheading:12069593-Adrenergic beta-Agonists, pubmed-meshheading:12069593-Amino Acid Sequence, pubmed-meshheading:12069593-Animals, pubmed-meshheading:12069593-Blotting, Western, pubmed-meshheading:12069593-Cell Line, pubmed-meshheading:12069593-Cricetinae, pubmed-meshheading:12069593-Cyclic AMP, pubmed-meshheading:12069593-Down-Regulation, pubmed-meshheading:12069593-Humans, pubmed-meshheading:12069593-Isoproterenol, pubmed-meshheading:12069593-Leupeptins, pubmed-meshheading:12069593-Molecular Sequence Data, pubmed-meshheading:12069593-Pepstatins, pubmed-meshheading:12069593-Protease Inhibitors, pubmed-meshheading:12069593-RNA, Messenger, pubmed-meshheading:12069593-RNA Stability, pubmed-meshheading:12069593-Receptors, Adrenergic, beta-1, pubmed-meshheading:12069593-Receptors, Adrenergic, beta-2, pubmed-meshheading:12069593-Thionucleotides
pubmed:year	2002
pubmed:articleTitle	Complexity of agonist- and cyclic AMP-mediated downregulation of the human beta 1-adrenergic receptor: role of internalization, degradation, and mRNA destabilization.
pubmed:affiliation	Membrane Biochemistry Section, Laboratory of Molecular and Cellular Neurobiology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 49 Convent Drive, MSC 4440, Bethesda, MD 20892, USA.
pubmed:publicationType	Journal Article, Comparative Study